[{"id":"5e6f3a26-4134-4064-8bdb-8aa37704f636","acronym":"CONVERCAP","url":"https://clinicaltrials.gov/study/NCT06705335","created_at":"2025-02-26T11:48:51.927Z","updated_at":"2025-02-26T11:48:51.927Z","phase":"","brief_title":"Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT06705335 - CONVERCAP","lead_sponsor":"Institut Bergonié","biomarkers":" CD8 • CD4 • VEGFC","pipe":"","alterations":" ","tags":["CD8 • CD4 • VEGFC"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2024-11-26"},{"id":"4629442d-297c-4cea-ba12-8b6c1e5ff2c5","acronym":"LENVABLA","url":"https://clinicaltrials.gov/study/NCT05113186","created_at":"2021-11-09T12:53:04.452Z","updated_at":"2025-02-25T13:35:59.564Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative","source_id_and_acronym":"NCT05113186 - LENVABLA","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" AFP • FLT4 • VEGFC","pipe":"","alterations":" ","tags":["AFP • FLT4 • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/02/2022","start_date":" 02/02/2022","primary_txt":" Primary completion: 07/02/2025","primary_completion_date":" 07/02/2025","study_txt":" Completion: 10/02/2026","study_completion_date":" 10/02/2026","last_update_posted":"2024-08-01"},{"id":"cd9b7f99-c8f6-4abc-a477-355dc349deae","acronym":"DUMELEP","url":"https://clinicaltrials.gov/study/NCT06045975","created_at":"2024-04-09T17:42:37.188Z","updated_at":"2025-02-25T15:01:05.349Z","phase":"Phase 2","brief_title":"Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation","source_id_and_acronym":"NCT06045975 - DUMELEP","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" FLT4 • VEGFC","pipe":"","alterations":" ","tags":["FLT4 • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/28/2024","start_date":" 03/28/2024","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2027","study_completion_date":" 09/28/2027","last_update_posted":"2024-07-31"},{"id":"3dd7c2f3-5edb-4afd-aab6-f0b5ef867dad","acronym":"","url":"https://clinicaltrials.gov/study/NCT03796273","created_at":"2021-01-18T18:46:15.719Z","updated_at":"2024-07-02T16:35:11.784Z","phase":"Phase 1","brief_title":"Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases","source_id_and_acronym":"NCT03796273","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" KDR • CD24 • POU5F1 • VEGFC","pipe":"","alterations":" ","tags":["KDR • CD24 • POU5F1 • VEGFC"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-04-03"},{"id":"796e83f4-6261-48e8-b340-ab87168b71d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03005860","created_at":"2021-01-18T14:47:05.738Z","updated_at":"2024-07-02T16:35:25.474Z","phase":"","brief_title":"Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery","source_id_and_acronym":"NCT03005860","lead_sponsor":"Tata Memorial Centre","biomarkers":" HIF1A • VEGFC","pipe":"","alterations":" ","tags":["HIF1A • VEGFC"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2023-12-21"},{"id":"369a58dd-4a69-448b-9669-35759434dc53","acronym":"TWICE-IRI","url":"https://clinicaltrials.gov/study/NCT04392479","created_at":"2021-01-18T21:11:59.050Z","updated_at":"2024-07-02T16:35:32.165Z","phase":"Phase 3","brief_title":"TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.","source_id_and_acronym":"NCT04392479 - TWICE-IRI","lead_sponsor":"GCS IHFB Cognacq-Jay","biomarkers":" KDR • FLT4 • VEGFC","pipe":"","alterations":" ","tags":["KDR • FLT4 • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 06/15/2023","primary_completion_date":" 06/15/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-10-23"},{"id":"b9fd1bb6-f212-4227-a1c0-e29d0c2b26d0","acronym":"AdeLE","url":"https://clinicaltrials.gov/study/NCT03658967","created_at":"2021-01-19T16:33:53.552Z","updated_at":"2024-07-02T16:35:32.534Z","phase":"Phase 2","brief_title":"Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)","source_id_and_acronym":"NCT03658967 - AdeLE","lead_sponsor":"Herantis Pharma Plc.","biomarkers":" VEGFC","pipe":"","alterations":" ","tags":["VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lymfactin (adAptVEGF-C adenoviral vector)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/07/2018","start_date":" 06/07/2018","primary_txt":" Primary completion: 12/16/2019","primary_completion_date":" 12/16/2019","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-10-19"},{"id":"3a1a5254-3234-4524-b5ba-287fea6ff089","acronym":"","url":"https://clinicaltrials.gov/study/NCT03823651","created_at":"2021-03-02T16:53:11.206Z","updated_at":"2024-07-02T16:35:58.847Z","phase":"","brief_title":"A Research Program Targeting Pre- and Peri-transplant Optimization Program (R-PPOP)","source_id_and_acronym":"NCT03823651","lead_sponsor":"Duke University","biomarkers":" IL6 • FLT1 • IL2 • IL10 • VEGFC • FGF • IL17A • IL23A • IL17C • IL21 • IL22 • TSLP • VCAM1 • IL16","pipe":"","alterations":" ","tags":["IL6 • FLT1 • IL2 • IL10 • VEGFC • FGF • IL17A • IL23A • IL17C • IL21 • IL22 • TSLP • VCAM1 • IL16"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/27/2019","start_date":" 06/27/2019","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-12-20"},{"id":"0c90cd30-d9b5-4626-af27-72cee25782de","acronym":"REBORN","url":"https://clinicaltrials.gov/study/NCT04464122","created_at":"2021-01-18T21:27:30.836Z","updated_at":"2024-07-02T16:36:00.020Z","phase":"","brief_title":"Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","source_id_and_acronym":"NCT04464122 - REBORN","lead_sponsor":"University of Roma La Sapienza","biomarkers":" KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3","pipe":"","alterations":" ","tags":["KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 09/14/2024","primary_completion_date":" 09/14/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-11-23"},{"id":"0778f69f-9b26-4fa2-8d42-2591932eddd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05560035","created_at":"2022-09-29T15:56:59.742Z","updated_at":"2024-07-02T16:36:03.186Z","phase":"","brief_title":"The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery","source_id_and_acronym":"NCT05560035","lead_sponsor":"General Hospital of Ningxia Medical University","biomarkers":" MMP2 • VEGFC • MMP9 • THBS2","pipe":"","alterations":" ","tags":["MMP2 • VEGFC • MMP9 • THBS2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-09-29"},{"id":"863f301c-d7ce-401c-a561-44e816aa2de5","acronym":"BOOSTER","url":"https://clinicaltrials.gov/study/NCT01989780","created_at":"2021-01-18T09:04:26.431Z","updated_at":"2024-07-02T16:36:06.061Z","phase":"Phase 2","brief_title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","source_id_and_acronym":"NCT01989780 - BOOSTER","lead_sponsor":"Japan Breast Cancer Research Group","biomarkers":" HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • fulvestrant • letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 160","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2022-08-04"},{"id":"50982497-d2f5-4ca8-ba80-094bc5c9d099","acronym":"","url":"https://clinicaltrials.gov/study/NCT04368546","created_at":"2021-01-18T21:06:06.081Z","updated_at":"2024-07-02T16:36:35.547Z","phase":"","brief_title":"Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)","source_id_and_acronym":"NCT04368546","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" VEGFC","pipe":"","alterations":" ","tags":["VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2021-01-27"},{"id":"66bc3f88-573e-483d-a074-c5b181266d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01297244","created_at":"2021-01-18T05:16:20.218Z","updated_at":"2024-07-02T16:36:39.586Z","phase":"Phase 2","brief_title":"A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT01297244","lead_sponsor":"AVEO Pharmaceuticals, Inc.","biomarkers":" HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68","pipe":"","alterations":" ","tags":["HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2020-10-27"},{"id":"f76845b1-ea5c-4ee7-9b14-d75b2ede7244","acronym":"","url":"https://clinicaltrials.gov/study/NCT01514123","created_at":"2021-01-18T06:21:50.486Z","updated_at":"2024-07-02T16:36:40.929Z","phase":"Phase 1","brief_title":"Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT01514123","lead_sponsor":"Circadian Technologies Ltd.","biomarkers":" KDR • FLT4 • VEGFD • VEGFC","pipe":"","alterations":" ","tags":["KDR • FLT4 • VEGFD • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 12/29/2011","start_date":" 12/29/2011","primary_txt":" Primary completion: 02/07/2014","primary_completion_date":" 02/07/2014","study_txt":" Completion: 11/16/2017","study_completion_date":" 11/16/2017","last_update_posted":"2020-09-17"},{"id":"60e1151a-f1e8-4130-93c4-041a8babe961","acronym":"tumorimmunity","url":"https://clinicaltrials.gov/study/NCT04518579","created_at":"2021-01-18T21:38:59.735Z","updated_at":"2024-07-02T16:36:41.742Z","phase":"","brief_title":"Epidural-inhalational Versus Epidural-intravenous Anaesthesia on Anti-tumor Immunity in Patients With Cancer Colon","source_id_and_acronym":"NCT04518579 - tumorimmunity","lead_sponsor":"South Egypt Cancer Institute","biomarkers":" CD8 • NCAM1 • VEGFC","pipe":" | ","alterations":" CD8 expression","tags":["CD8 • NCAM1 • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 04/15/2018","start_date":" 04/15/2018","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 08/01/2020","study_completion_date":" 08/01/2020","last_update_posted":"2020-08-21"},{"id":"931a0803-d4c8-4f98-9bb6-97e87c40e482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01956669","created_at":"2021-01-18T08:52:55.254Z","updated_at":"2024-07-02T16:36:42.063Z","phase":"Phase 2","brief_title":"Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors","source_id_and_acronym":"NCT01956669","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KIT • KDR • AFP • FLT1 • VEGFC • FGF","pipe":"","alterations":" ","tags":["KIT • KDR • AFP • FLT1 • VEGFC • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 10/08/2014","start_date":" 10/08/2014","primary_txt":" Primary completion: 11/05/2019","primary_completion_date":" 11/05/2019","study_txt":" Completion: 11/05/2019","study_completion_date":" 11/05/2019","last_update_posted":"2020-08-12"},{"id":"4c00001e-31a5-4a83-a133-6511b2290c05","acronym":"","url":"https://clinicaltrials.gov/study/NCT02829333","created_at":"2021-01-19T12:30:54.224Z","updated_at":"2024-07-02T16:36:51.083Z","phase":"","brief_title":"The Effect of Anesthetic Technique on VEGF-C and PGE2","source_id_and_acronym":"NCT02829333","lead_sponsor":"General Hospital of Ningxia Medical University","biomarkers":" VEGFC","pipe":"","alterations":" ","tags":["VEGFC"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2020-01-22"},{"id":"b90c7697-6311-4262-9536-bc47534419d3","acronym":"AMALTHEA","url":"https://clinicaltrials.gov/study/NCT02129257","created_at":"2021-01-18T09:52:23.572Z","updated_at":"2024-07-02T16:37:16.932Z","phase":"Phase 2","brief_title":"Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT02129257 - AMALTHEA","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" KDR • HGF • HIF1A • FLT1 • VEGFB • VEGFC • FGF • NRP1","pipe":"","alterations":" ","tags":["KDR • HGF • HIF1A • FLT1 • VEGFB • VEGFC • FGF • NRP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 05/26/2014","start_date":" 05/26/2014","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 09/25/2017","study_completion_date":" 09/25/2017","last_update_posted":"2017-10-24"}]